Cardiovascular disease
NewAmsterdam Pharma B.V. focuses on clinical research in atherosclerotic cardiovascular disease, with attention to coronary artery plaque burden, arterial narrowing, and broader cardiovascular risk in adults receiving lipid-lowering treatment.
- Atherosclerotic cardiovascular disease
- Coronary atherosclerosis
- Non-calcified plaque
The sponsor’s studies include outcomes related to coronary plaque characteristics and the progression of atherosclerotic heart and blood vessel disease.
Lipid management
Its research activity is centered on LDL cholesterol reduction in participants whose current lipid-modifying therapy is not sufficiently effective, including people with persistent elevated LDL-C.
- LDL-C lowering
- Lipid-modifying therapy
- Combination lipid therapy
Clinical interest extends to fixed-dose combination approaches and monotherapy strategies aimed at improving lipid control.
Metabolic disease
The sponsor also studies adults with type 2 diabetes and metabolic syndrome, reflecting an interest in cardiometabolic conditions linked to dyslipidemia and vascular disease.
- Type 2 diabetes
- Metabolic syndrome
- Cardiometabolic risk
These programs address patients whose metabolic disorders coexist with elevated cardiovascular risk and abnormal lipid profiles.
Cardiovascular outcomes
Research interests include prevention of major adverse cardiovascular events, with focus on myocardial infarction, stroke, cardiovascular death, and coronary revascularization.
- Major adverse cardiovascular events
- Myocardial infarction
- Stroke
These studies link lipid lowering with clinically meaningful cardiovascular event reduction in patients with established vascular disease.
